Myriad Genetics and Qiagen to co-develop HRD test

Qiagen (QGEN) and Myriad Genetics (MYGN) will develop a globally distributable kit-based test for analyzing Homologous Recombination Deficiency – HRD – status. This next-generation sequencing – NGS – test aims to support research into personalized medicine in multiple solid tumor types, including ovarian cancer and is expected to enhance decentralized testing capacities once a regulated product is developed with pharmaceutical partners. The project builds on the master collaboration agreement between the two companies. The test will be based on Qiagen’s QIAseq xHYB technology, Qiagen Digital Insight solutions, and Myriad’s proprietary FDA-approved MyChoice CDx, a single-site PMA-approved centralized testing service for analyzing HRD in certain tumors. Qiagen will manage the development and distribution of the kit-based HRD test outside of the U.S. The IP license grants Qiagen the capability to collaborate with pharmaceutical partners to create an IVD-validated test, intended for use as a companion diagnostic outside of the U.S.